National Vision vs STAAR Surgical
EYE and STAA side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EYE and STAA compare
National Vision and STAAR Surgical are about the same size, with market caps of $1.4B and $1.3B.
STAAR Surgical grew revenue faster over the last twelve months (42.4% versus 7.0% for National Vision).
National Vision keeps more of each dollar of sales as profit, with a net margin of 3.2% compared with 0.16% at STAAR Surgical.
National Vision scores higher on the StockData Score (13 against 8 for STAAR Surgical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EYE | STAA |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $1.3B |
| Share price | $18.09 | $26.69 |
| Change, 1 year | −25.1% | −2.6% |
| Change, 5 years | −62.8% | −75.7% |
| Beta (5Y) | 0.97 | 1.48 |
| Employees | 13K | 957 |
| StockData Score | ||
| Total score | 13 (better) | 8 |
| Valuation score | 6 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 22.3× | – |
| P/S | 0.7× (better) | 4.1× |
| P/B | 1.6× (better) | 3.6× |
| EV/EBITDA | 8.1× (better) | 1615× |
| P/FCF | 21.0× (better) | 75.0× |
| FCF yield | 4.8% (better) | 1.3% |
| Fair value | $30.39 | – |
| Margin of safety | 40.5% | – |
| Growth | ||
| Revenue growth (TTM) | 7.0% | 42.4% (better) |
| Revenue growth, 5Y average | 3.0% | 7.9% (better) |
| EPS growth, 5Y average | −3.4% | – |
| Profitability | ||
| Gross margin | 58.8% | 73.6% (better) |
| Operating margin | 5.1% (better) | 0.21% |
| Net margin | 3.2% (better) | 0.16% |
| FCF margin | 3.3% | 5.4% (better) |
| Return on equity | 7.5% (better) | 0.15% |
| Return on invested capital | 7.2% (better) | 0.21% |
| Financial health | ||
| Debt / equity | 0.25 (better) | 0.00 |
| Net debt / EBITDA | 0.85 | – |
| Current ratio | 0.63 | 4.68 (better) |
| Altman Z-score | 2.11 | 8.36 (better) |
| Piotroski F-score | 8 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 3.7% | – |
| Shareholder yield | 3.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 126% | 110% |
| Held by insiders | 2.5% | – |
| Insider net buying, 12 months | −$498K | $21.7M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 21.3% | – |
Go deeper
- EYE stock overview
- EYE income statement
- EYE valuation and score
- STAA stock overview
- STAA income statement
- STAA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.